Peer-reviewedCC BY 4.0Translational Psychiatry
Worldwide use of long-acting injectable antipsychotics in schizophrenia: a systematic review and meta-analysis
Related
- Total cost of care for long-acting injectable antipsychotics for schizophrenia: Pharmacy vs medical benefit
- Pathways to medication adherence: a configurational analysis of psychiatric symptoms and medication attitude in patients with schizophrenia spectrum disorder receiving long-acting injectable antipsychotics.
- Long-acting injectable antipsychotics linked to reduced short-term disruptive life event and death
- Perceptions of psychiatrists toward long-acting injectable antipsychotics: A cross-sectional survey from Fujian, China
- Clinical Course and Discontinuation of Olanzapine Long-Acting Injectable: A Retrospective Case Series Including a Case of Post-Injection Delirium/Sedation Syndrome
BibTeX
@article{chen2026worldwide,
title = {{Worldwide use of long-acting injectable antipsychotics in schizophrenia: a systematic review and meta-analysis}},
author = {Xiaobao Chen and Yubin Chen and Ying Wu and Linghui Zhang and Minle Lu and Junhui Dong and Lingxi Wang and Hao Sun and Wenlong Jiang and Yuqiu Zhou},
journal = {Translational Psychiatry},
year = {2026},
month = nov,
doi = {10.1038/s41398-026-04571-9},
url = {https://www.nature.com/articles/s41398-026-04571-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Worldwide use of long-acting injectable antipsychotics in schizophrenia: a systematic review and meta-analysis
AU - Xiaobao Chen
AU - Yubin Chen
AU - Ying Wu
AU - Linghui Zhang
AU - Minle Lu
AU - Junhui Dong
AU - Lingxi Wang
AU - Hao Sun
AU - Wenlong Jiang
AU - Yuqiu Zhou
PY - 2026
DA - 2026/11/16
JO - Translational Psychiatry
DO - 10.1038/s41398-026-04571-9
UR - https://www.nature.com/articles/s41398-026-04571-9
SN - 2158-3188
ER -